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Abstract Paclitaxel is an anticancer agent efficacious in the
treatment of ovarian, breast, and lung cancer. Due to a strong
link between the pharmacokinetics and therapeutic efficacy of
paclitaxel, we reviewed the literature on paclitaxel pharma-
cokinetics. Systematic data mining was performed to extract
the maximum concentration (Cmax), clearance (CL), and time
of paclitaxel plasma concentration above 0.05 lmol/L
(T[0.05 lmol/L) followingmonotherapy of both the widely
used cremophor-diluted paclitaxel and nanoparticle albumin-
bound (nab-)paclitaxel. We identified a total of 53 studies
yielding 121 aggregated pharmacokinetic profiles for pacli-
taxel monotherapy and extracted reported mean and median
estimates of pharmacokinetic parameters. Paclitaxel has been
studied formally at doses of 15–825 mg/m2 and infused over
0.5–96 h; included studies examined both weekly and every
3-weeks dosing cycles. The most widely used dose of cre-
mophor-diluted paclitaxel, 175 mg/m2 given as a 3-h infusion,
leads to an interstudymedianCmax of 5.1 lmol/L [interquartile
range (IQR) 4.5–5.7], CLof 12.0 L/h/m2 (IQR10.9–12.9), and
T[0.05 lmol/L of 23.8 h (IQR 21.5–26.8). Importantly, the
significant interindividual variation widely reported in the lit-
erature is not reflected in these interstudy estimates of phar-
macokinetic parameters. Cremophor-diluted paclitaxel
pharmacokinetics are non-linear following short (\6 h)but not
long ([24 h) infusions. A similar pattern of non-linearity was
observed for nab-paclitaxel, although the number of studies
was limited. The pharmacokinetics of paclitaxel monotherapy
have been widely studied at numerous dose levels of the Cre-
mophor EL formulation, but are less well-characterized for
the newer nab-paclitaxel formulation. In conclusion, paclitaxel
pharmacokinetics are non-linear for short infusion times but
not for longer infusions. Whether a similar conclusion can be
drawn for nab-paclitaxel formulations requires further study.
Key Points
The time above a threshold paclitaxel plasma
concentration (0.05 lmol/L) is important for the
efficacy and toxicity of the drug.
Paclitaxel is administered mainly as two
formulations: Cremophor EL diluted or
nanoparticle albumin bound. The cremophor-diluted
formulation has been widely tested at different doses
and infusion times; data are more limited for the
nanoparticle formulation.
The plasma concentrations of paclitaxel do not
follow linear pharmacokinetics for short infusions.
This is particularly evident for cremophor-based
paclitaxel.
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1 Background
Paclitaxel is a widely used drug in the treatment of breast
[1], ovarian [2], and lung cancer [3]. Paclitaxel binds to and
promotes the assembly of tubulin into dysfunctional
microtubules, which leads to chromosome missegregation
on multipolar spindles at clinically observed concentrations
[4]. The consequence of microtubule dysfunction is inhi-
bition of mitosis and cell proliferation, resulting in the
death of rapidly proliferating tumor cells.
Paclitaxel is a high molecular weight drug (853.9 g/mol)
with a very low solubility in water (0.7 mg/mL) [5]. It is
metabolized primarily by cytochrome P450 (CYP) 2C8 to
the largely inactive metabolite 6-hydroxypaclitaxel and to a
lesser degree by CYP3A4 to 30-phenyl-hydroxypaclitaxel
[6]. Paclitaxel is a substrate for ATP-binding cassette
(ABC) efflux transporters, including multidrug resistance
protein 1 [MDR1/P-glycoprotein (P-gp), ABCB1] [7, 8],
breast cancer resistance protein (BCRP, ABCG2) [9], and
multidrug resistance-associated proteins 1/2 (MRP1/2,
ABCC1/C2) [10, 11]. ABC transporter-mediated efflux of
paclitaxel back into the intestinal lumen accounts for its
very low oral bioavailability and requirement for intra-
venous administration. The influx transporter organic anion
transporter (OAT) polypeptide 1B3 (OATP1B3,
SLCO1B3) has been shown to be involved in the hepatic
uptake of paclitaxel [12, 13]; paclitaxel is also a substrate
for the renal OAT2 (SLC22A7) [14]. Activity of these
hepatic and renal transporters may play an important role in
the distribution and elimination of paclitaxel and may
contribute to variability in the pharmacokinetics of the
drug. Paclitaxel activates pregnane X receptor (PXR)
[15, 16], leading to upregulation of key drug-metabolizing
enzymes such as CYP3A4 [16, 17] and transporters such as
ABCB1 [15]. However, the administration of paclitaxel
every 1, 2, or 3 weeks has not been associated with altered
metabolism over time [18–21], suggesting that autoinduc-
tion is minimal during standard dosing conditions.
Due to the hydrophobic nature of paclitaxel, it was
originally diluted in the solvent Cremophor EL, a poly-
oxy-ethylated oil mixed 1:1 with ethanol. This formulation
solves one problem, but is associated with hypersensitivity
reactions to Cremophor EL. This was initially circum-
vented by using longer infusions times. However, the
addition of pretreatment with prophylactic antihistamines
(both histamine H1 and H2 receptor antagonists) and glu-
cocorticoids has made it possible to reduce infusion times
and achieve similarly low rates of hypersensitivity reac-
tions [22]. Recently, a nanoparticle albumin-bound for-
mulation of paclitaxel (nab-paclitaxel) was developed that
does not cause infusion hypersensitivity reactions and thus
eliminates the need for prophylactic treatment. Paclitaxel is
highly bound (90%) to plasma proteins [23], and the free
fraction of paclitaxel inversely correlates with Cremophor
EL concentrations [24, 25].
The paclitaxel response rate differs significantly
between cancers, with ovarian cancer generally more sen-
sitive than breast cancer [26, 27]. Efficacy and toxicity also
depends on combination with other chemotherapeutic
agents and even the sequence of chemotherapy adminis-
tration. For example, in one study the clearance (CL) of
paclitaxel was lower when administered after cisplatin
compared to administration before the platinum agent [28],
though this effect was not replicated in another study [29].
Significant interpatient variability is also observed for
paclitaxel adverse events, although the frequency and
severity is quite similar across cancer types. The most
common and problematic adverse event is peripheral sen-
sory neuropathy, with significant neutropenia also
observed. Both peripheral neuropathy and neutropenia are
dose limiting and lead to reduced response rates to pacli-
taxel. Based on a database of 812 patients with various
solid tumors treated with single-agent paclitaxel, severe
neutropenia (\500 cells/cm3) occurred in 52% of the
patients. Peripheral neuropathy was reported for 60% of the
patients treated with mixed doses (135–300 mg/m2) and
infusion times (3 or 24 h), with 3% reporting severe
(grade 3 or higher) neuropathy [30]; these frequencies are
known to vary significantly between populations. Clinical
symptoms of neuropathy range from numbness and tingling
in fingers and hands to cold or heat intolerance and burning
pain. Normally, neuropathy symptoms are reversible, but
some patients continue to experience neuropathy up to
2 years after drug cessation, significantly impairing quality
of life [31].
The reasons for variability in paclitaxel response and
toxicity are multifaceted. Some studies have suggested that
polymorphisms in CYP2C8 or ABCB1 cause pharmacoki-
netic variation, while others show no effect. Even when a
pharmacogenetic difference in paclitaxel pharmacokinetics
has been demonstrated, such as for CYP2C8*3 (and *4),
clinical relevance is limited because of the small effect size
[32]. Recent genome-wide association studies (GWAS)
have found a multitude of genetic variants associated with
risk of peripheral neuropathy during treatment with pacli-
taxel [33–35]. Some findings are biologically plausible,
such as variants in genes involved in neuronal repair, while
others require further investigation to fully understand their
relevance. These hypothesis-generating studies are of merit
as they might provide new insight into the molecular
mechanisms underlying the toxicities; however, substantial
validation in multiple cohorts is required before their final
interpretation and potential translation into clinical
practice.
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Drug–drug interactions (DDIs) affecting the pharma-
cokinetics of paclitaxel have not been systematically
studied, likely because of ethical considerations of testing
potentially harmful DDIs in cancer patients. Clinicians
often extrapolate from case observations, in vitro data, and
limited epidemiological studies to optimally manage
polytherapy during cancer treatment. For example, a
metabolite of clopidogrel that inhibits CYP2C8 in vitro
was linked to a very low CL of paclitaxel and increased
risk of neuropathy in an ovarian cancer patient [36]. This
was later supported by a small case series in which seven
out of eight patients treated with clopidogrel and paclitaxel
experienced grade 3 neutropenia [37]. More recently, 48
patients treated with paclitaxel and clopidogrel were found
to have increased rates of neuropathy compared with a
control group of 88 patients using low-dose aspirin in place
of clopidogrel. The study concluded that the risk of
peripheral neuropathy is approximately two-fold higher in
patients using clopidogrel and paclitaxel in doses of
135 mg/m2 or greater [38].
The pharmacokinetics of paclitaxel are known to cor-
relate with treatment response [39, 40] and adverse effects
[41–44]. Thus, a comprehensive understanding may lead to
improved treatment outcomes. The pharmacokinetics of
paclitaxel were comprehensively reviewed by Sonnichsen
and Relling [45] in 1994. However, a large number of
paclitaxel pharmacokinetic studies have been published
since and a new formulation, nab-paclitaxel, has been
introduced to the market. These updates are captured in the
current literature review, along with a systematic analysis
of paclitaxel CL, maximum plasma concentration (Cmax),
and time of paclitaxel plasma concentration above
0.05 lmol/L (T[ 0.05 lmol/L) for a range of doses of
cremophor-diluted and albumin-bound paclitaxel given as
single-agent therapy.
2 Methods
PubMed was searched with the following sequence: (Pa-
clitaxel or Taxol) AND pharmacokinetics [(MESH) or (All
fields)] and restricted to clinical trials in English with
human subjects. The search was performed on 21 June
2016 and gave a total of 608 hits. Titles and abstracts for
studies with any formulation of paclitaxel were evaluated
twice by two independent reviewers and identified 322
publications for further consideration. Papers without
abstracts were only included if it was clear from the title
that they would be relevant. Full texts were then read by at
least one reviewer and 182 publications were identified that
described a minimum of 6 h of pharmacokinetic sampling
for paclitaxel or nab-paclitaxel. After exclusion of studies
where paclitaxel was not given as monotherapy or
pharmacokinetic parameters were not available, 53 publi-
cations remained [19, 21, 46–96] and serve as the basis for
this review (Fig. 1).
The following information was extracted from all pub-
lications: number of patients, duration of infusion (h),
formulation of paclitaxel (cremophor-diluted or nab-pa-
clitaxel), dose (mg/m2), Cmax (lmol/L), total CL (L/h/m
2),
and T[ 0.05 lmol/L (h). In cases where a single publi-
cation had pharmacokinetic profiles at different dose levels,
every dose level was included separately. In studies with
repeated pharmacokinetic profiles, only the first visit was
included. Since data presentation varied among included
publications, both median and mean estimates were
extracted and pooled for analysis. Therefore, the summary
values for all parameters reported here reflect interstudy
variation and provide no indication of the significant
interindividual variation in paclitaxel pharmacokinetics
that is widely reported.
Correlation between dose and Cmax was evaluated by
linear and quadratic fits and r2 was used to evaluate the best
fit (STATA 14.2, StataCorp, College Station, TX, USA).
Fig. 1 Flowchart showing overview of literature search. The criteria
for inclusion of papers for the final analysis are outlined as an iterative
process. IV intravenous, PK pharmacokinetic
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3 Results
An overview of included publications and the corresponding
data extracted from these studies are provided as Electronic
Supplementary Material (Online Resource 1). Briefly, 53
papers yielded a total of 121 pharmacokinetic profiles with a
median number of six patients [interquartile range (IQR)
3–10 patients] in each study. Pharmacokinetic parameters
presented in this paper are medians with IQRs (25th–75th
percentiles), unless otherwise specified. A study with sub-
therapeutic radiolabeled paclitaxel [64] was not included in
the analysis due to the nature of the paclitaxel formulation.
Thus, 120 profiles were included in the final analysis.
3.1 Cremophor EL Paclitaxel
A total of 104 pharmacokinetic profiles for Cremophor
EL paclitaxel from administration of 32 different doses
(15–825 mg/m2) over six different infusion times (1, 3, 6,
24, 72, and 96 h) were evaluated. The diversity of pacli-
taxel dosage regimens is illustrated in Fig. 2.
Ninety-one paclitaxel CL estimates were extracted from
the included studies [67 for short infusion (B6 h) and 24
for long infusion ([6 h)]. Figure 3 shows the relationship
between CL and dose for short and long infusion of Cre-
mophor EL paclitaxel. A single CL estimate was exclu-
ded from Fig. 3b (8.1 L/h/m2 for paclitaxel 825 mg/m2) to
limit the range of the dose-axis and allow for more accurate
representation of the majority of the data with lower doses.
Paclitaxel CL decreases up to three-fold with increasing
dose, which is most evident with shorter infusion times
(Fig. 3a). Furthermore, for a given dose, paclitaxel CL is
approximately two-fold higher when given as a long
infusion than as a short infusion.
The relationship between paclitaxel Cmax and dose is
illustrated in Fig. 4 for short (n = 75) and long (n = 24)
infusion times. A quadratic equation best described the
Cmax–dose relationship for paclitaxel given as a short
infusion; the data for the 1-h infusion time best fit this
relationship (r2 = 0.99). With a 1.7-fold increase in
paclitaxel dose given as 3-h infusion the Cmax increases
three-fold (Table 1). In contrast, a linear relationship pro-
vides the best fit for data from long infusion times. Cmax
values for long infusions were approximately tenfold lower
than for short infusions (Fig. 4). A single dose from the
long infusion data (825 mg/m2) was removed from Fig. 4b
to better illustrate the relationship for the majority of the
values.
The non-linearity in paclitaxel pharmacokinetics is also
highlighted in Table 1 with data from the most commonly
used infusion time, 3 h. Median values with corresponding
IQR (25th–75th percentiles) for Cmax and CL indicate a
greater than dose-proportional increase in Cmax and
decrease in CL with increasing dose.
In comparison to CL and Cmax, T[ 0.05 lmol/L was
less commonly reported for the paclitaxel pharmacokinetic
studies included in this analysis. Only 28 values for
T[ 0.05 lmol/L paclitaxel were reported, 21 for short and
seven for long infusion times (Fig. 5). Interestingly,
increasing infusion time from 3 to 24 h does not substan-
tially increase T[ 0.05 lmol/L. All values for
T[ 0.05 lmol/L from a 24-h infusion are from the same
study [90].
3.2 Nab-Paclitaxel
Pharmacokinetic data for nab-paclitaxel were extracted
from 16 studies using nine different doses (80–375 mg/
m2). The majority of these studies (n = 14) used a 0.5-h
infusion; a single study used a 3-h infusion and the
remaining study did not indicate an infusion time and was
excluded from further analysis. The relationship between
nab-paclitaxel CL and dose is illustrated in Fig. 6. With
nab-paclitaxel doses above 200 mg/m2, the CL of nab-pa-
clitaxel decreases in a similar fashion as described for the
Cremophor EL paclitaxel formulation. Non-linearity was
also observed for paclitaxel Cmax values over a [4-fold
range of nab-paclitaxel doses (Fig. 7), although the
increases in Cmax were less striking than those observed
with the cremophor-diluted formulation (Fig. 4).
3.3 Population Pharmacokinetic Modelling
Six population pharmacokinetic studies of paclitaxel
monotherapy were identified [96–101] and these are
Fig. 2 Distribution of dosage regimens for cremophor-diluted pacli-
taxel included in this analysis. The solid line represents the median
dose, the box represents the interquartile range (25th–75th per-
centiles), and the whiskers represent 5th–95th percentiles. A single
outlier with a dose of 825 mg/m2 infused over 24 h is excluded due to
extension of the dose-axis and compression of the majority of the data
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summarized in Table 2. Briefly, all but one of the studies
had dense sampling with study populations ranging from
seven to 150 individuals. The final models included two or
three compartments with unique sets of covariates. One
study developed a semi-mechanistic model with paclitaxel
in four different states: peripheral or central and vehicle
bound or not vehicle bound [100]. In one case, elimination
was considered to be saturable and represented by
Michaelis–Menten pharmacokinetics [99]. The estimates of
CL and volume of distribution varied significantly across
the models.
4 Discussion
In this review of paclitaxel pharmacokinetics, data were
extracted from 53 papers reporting paclitaxel administra-
tion as single-agent chemotherapy with either cremophor-
Fig. 3 Dose-dependent
clearance of Cremophor-EL
paclitaxel. Paclitaxel clearance
(L/h/m2) plotted as a function of
dose for short (B6 h) (a) and
long ([6 h) (b) infusion times
Fig. 4 Maximum paclitaxel
concentrations are not dose
proportional with short infusion
times. Maximum concentration
(lmol/L) of paclitaxel during
short (a) and long (b) infusion is
expressed as a function of dose
and infusion time. Solid lines
represent a quadratic fit for short
infusion times and a linear fit for
long infusion times. Cmax
maximum concentration
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diluted or nab-paclitaxel-bound paclitaxel. The effect of
dose and infusion time on CL, Cmax and T[ 0.05 lmol/L
were the main outcomes analyzed. Based on 120
pharmacokinetic profiles for cremophor-diluted and nab-
paclitaxel, paclitaxel CL is non-linear over commonly used
doses and infusion times. Non-linear paclitaxel CL results
in more than dose-proportional increases in Cmax, which is
particularly apparent when paclitaxel is administered as the
Cremophor EL formulation. The most widely used
dosage regimen for cremophor-diluted paclitaxel is a 3-h
infusion of 175 mg/m2. This popular dosage regimen cor-
responds to median values for CL, Cmax, and
T[ 0.05 lmol/L of 12 L/h/m2, 5 lmol/L, and 24 h,
respectively. Increasing infusion time from 3 to 24 h does
not significantly increase T[ 0.05 lmol/L, and with the
implementation of glucocorticoid and antihistamine pre-
treatment to reduce hypersensitivity reactions, there is little
support for longer infusion times. While non-linear CL was
also observed with high doses of the nab-paclitaxel for-
mulation, non-linearities in Cmax were less pronounced.
The average Cmax of the four patients who received a dose
of 375 mg/m2 in the study by Ibrahim et al. [73] was
22.6 lmol/L. Without this observation, the nab-paclitaxel
Table 1 Pharmacokinetic parameters for cremophor-diluted paclitaxel following a 3-h infusion at commonly used dose levels
Dose level (mg/m2)a Cmax (lmol/L) CL (L/h/m
2) T[ 0.05 lmol/L (h)
n Median (25th–75th percentile) n Median (25th–75th percentile) n Median (25th–75th percentile)
135 6 3.1 (2.7–3.3) 6 15.5 (13.1–16.7)
175 18 5.1 (4.5–5.7) 17 12.0 (10.9–12.9) 4 23.8 (21.5–26.8)
210 4 7.7 (6.7–8.6) 5 10.1 (9.7–10.7)
225 4 8.2 (7.3–10.3) 3 9.8 (8.5–11.6)
240 3 9.6 (9.0–9.6) 3 4.8 (4.8–9.1)
CL clearance, Cmax maximum concentration, n number of studies, T[ 0.05 lmol/L time of paclitaxel plasma concentration above 0.05 lmol/L
a More than three studies at a given dose were required for inclusion
Fig. 5 The time of Cremophor-EL paclitaxel concentration above
0.05 lmol/L plotted as a function of dose and infusion time shows
that the time of paclitaxel concentration above 0.05 lmol/L is largely
independent of infusion time
Fig. 6 Non-linear clearance of paclitaxel administered in its nanopar-
ticle albumin-bound formulation
Fig. 7 Relationship between paclitaxel maximum concentration
(lmol/L) values and dose following nanoparticle albumin-bound
paclitaxel administration given as a function of dose and infusion
time. Cmax maximum concentration
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Table 2 Overview of population pharmacokinetic models describing single agent cremophor-diluted or nanoparticle albumin-bound paclitaxel
therapy. All studies used the software package NONMEM
Studied population Sex
(%
male)
Paclitaxel dose
(mg/m2) and
infusion time
Structural
model
Clearance
estimatesa
Volume of
distribution
estimatesb
Significant covariates References
Cremophor-diluted paclitaxel
N = 7
Bladder, breast, lung,
and other
malignancies
43 225, 175, and
135 over 3-h
infusion
3-compartment CLc (±SD):
71 ± 13 L/
h
Q1 (±SD):
30 ± 8 L/h
Q2 (±SD):
34 ± 8 L/h
V1 (±SD):
41 ± 14 L
V2 (±SD):
51 ± 14 L
V3 (±SD):
340 ± 81 L
No covariates other
than Cremophor
EL were tested
[96]
N = 18
Unknown malignancies
66 20–50 over 1-h
infusion
2-compartment CLTotal:
6.71 L/h
(70%)
Q1Total:
44.7 L/h
(126%)
V1: 3.64 L
(79%)
V2: 881 L
(NA)
None [97]
N = 45
Colorectal, gastric, gall
bladder, breast,
uterine, ovarian, and
pancreas cancer
31 175 over 3-h
infusion
2-compartment CLunbound:
343 L/h
(3.5%)
Qunbound:
188 L/h
(13%)
V1unbound:
418 L (7.1%)
V2unbound:
1010 L
(4.2%)
Body surface area on
CL, V1, and V2, and
bilirubin on CL. a-1
acid glycoprotein on
Bmax
[101]
N = 97d
Breast, ovarian,
esophagus, and other
malignancies
41 50–225 over 1-h
(n = 42), 3-h
(n = 49), or
24-h (n = 6)
infusion
3-compartment CLunbound:
301 L/h
(4.3%)
Q1unbound:
132 L/h
(6.6%)
Q2unbound:
151 L/h
(6.5%)
V1unbound:
225 L (6%)
V2unbound:
3450 L
(7.8%)
V3unbound:
303 L (6.6%)
None [98]
N = 35
Breast, ovarian,
gastrointestinal, and
other solid
malignancies;
multiple stages of
liver dysfunction
22 70–175 over 3-h
infusion
3-compartment
with
Michaelis–
Menten
elimination
Vmax:
6.4 lmol/h
(17.3%)
KMEl:
0.06 lmol/L
(35%)
VTr:
161 lmol/h
(13.2%)
KMTr:
0.55 lmol/L
(13.4%)
k21: 1.2 h
-1
(12.5%)
Q: 16.1 L/h
(8.82%)
V1: 10.2 L
(15.3%)
V3: 642 L
(19.7%)
Sex, body surface
area, and liver
function for Vmax
[99]
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Cmax approached a non-linear pattern similar to that of
cremophor-diluted paclitaxel. Further studies are needed to
fully understand the relationship between nab-paclitaxel
dose and Cmax.
The main limitation of this analysis is the exclusion of
papers where paclitaxel was given concomitantly with other
chemotherapeutics. This limitation was necessary to limit
variability in paclitaxel pharmacokinetic parameters and to
identify robust dose-dependent changes in paclitaxel elimi-
nation. The strong correlation between Cmax and dose for a
given short infusion time (Fig. 4a) supports the study design
that was utilized. Furthermore, data regarding
interindividual variability in paclitaxel pharmacokinetics
were not widely available for the included studies. Both
medians and means from pooled data in each study were
used for the analyses described in this review. Thus, all
measures for variability presented in the current study reflect
interstudy variability rather than interpatient variability.
The main strength of this study is the number and
diversity of paclitaxel pharmacokinetic profiles that were
analyzed. Data were included for more than 30 different
doses and six different infusion times, representing the
most extensive analysis to date of single-agent paclitaxel
pharmacokinetics. This allows for the detection of strong
Table 2 continued
Studied population Sex
(%
male)
Paclitaxel dose
(mg/m2) and
infusion time
Structural
model
Clearance
estimatesa
Volume of
distribution
estimatesb
Significant covariates References
N = 38
Advanced or metastatic
solid tumors
NA 175 over 3-h
infusion
Semi-
mechanistic
model with 4
compartments
CL (90% CI):
101.0 L/h
(83.8–113.4)
Q1 (90% CI):
10.9 L/h
(8.3–14.3)
Q2 (90% CI):
0.6 L/h
(0.1–7.4)
Q3 (90% CI):
42.0 L/h
(33.3–50.0)
V1 (90% CI):
24.8 L
(18.2–32.1)
V2 (90% CI):
271.0 L
(183.1–447.8)
V3 (90% CI):
16.5 L
(0.4–56.9)
V4 (90% CI):
178.0 L
(146.3–319.1)
None [100]
Nanoparticle albumin-bound paclitaxel
N = 150
Advanced or metastatic
breast, melanoma, or
other solid tumors
40 80–375 over
30-min
infusion,
infusion time
was 3 h in 1
individual
Semi-
mechanistic
model with 4
compartments
CL (90% CI):
260 L/h
(226–307)
Q1 (90% CI):
39.4 L/h
(32.7–46.3)
Q2 (90% CI):
7.2 L/h
(1.7–12.0)
Q3 (90% CI):
49.6 L/h
(44.4–55.6)
V1 (90% CI):
11.8 L
(10.5–13.5)
V2 (90% CI):
270.6 L
(192.8–367.0)
V3 (90% CI):
169.6 L
(133.5–195.0)
V4 (90% CI):
399.1 L
(300.8–507.6)
None [100]
Bmax maximal non-linear binding to plasma components, CI confidence interval, CL clearance, CLtotal total clearance, CLunbound unbound
clearance, KMEL plasma concentration at half of the maximal elimination rate, KMTr plasma concentration at half VTr, k21 transfer rate constant
(first-order) from the peripheral to central compartment, NA not available, Q intercompartmental clearance, Q1total total intercompartmental
clearance in compartment 1, Q1unbound unbound intercompartmental clearance in compartment 1, Q2unbound unbound intercompartmental
clearance in compartment 2, Qunbound unbound intercompartmental clearance, RSE relative standard error, SD standard deviation, V1 volume of
compartment 1, V2 volume of compartment 2, V3 volume of compartment 3, V4 volume of compartment 4, V1unbound unbound volume of
compartment 1, V2unbound unbound volume of compartment 2, V3unbound unbound volume of compartment 3, Vmax maximum rate, VTR maxi-
maltransport rate from the central to the first peripheral compartment
a Data are shown as mean (RSE%) unless otherwise specified
b Data are shown as population estimate (RSE%) unless otherwise specified
c Overall CL based on unbound (non-micellar) paclitaxel
d 15 of 82 (18%) were also treated with carboplatin
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correlations between paclitaxel dose and Cmax and clearly
illustrates that paclitaxel CL is dose dependent, with CL
decreasing with increasing dose. The robustness of the
analyses is even more striking, considering that the data
was from more than 50 studies performed between 1991
and 2015 that employed a wide range of drug assays and
dosage regimens. Patient heterogeneity with respect to age,
ethnicity, co-morbidities, and treatment indication was also
significant. The conclusions drawn from the current anal-
ysis can therefore be applied broadly across diverse patient
populations and a broad range of paclitaxel dosage regi-
mens. Due to the nature of the data mining implemented in
this study, the results do not provide insight regarding
interpatient variability.
The non-linearity of paclitaxel pharmacokinetics, which
is easily visible for both Cmax and CL (Figs. 3, 4), was first
recognized in the 1990s [67]. Initial reports suggested
saturation of CYP-mediated metabolism of paclitaxel, but
the non-linear CL is now largely attributed to the formu-
lation of paclitaxel. Because of the high hydrophobicity of
paclitaxel, it requires dilution in Cremophor EL, a poly-
oxy-ethylated oil mixed 1:1 with ethanol. Free concentra-
tions of paclitaxel are inversely correlated with Cremophor
EL concentrations [102], which means that less paclitaxel
is available for distribution at higher doses. As a result,
tissue distribution and pharmacodynamics are largely
assumed to be linear. In this review, we see indications of
non-linear CL of nab-paclitaxel at higher doses, which
could indicate saturation of metabolism at high paclitaxel
concentrations. Gemfibrozil, another CYP2C8 substrate, is
known for non-linear pharmacokinetics [103, 104] at
higher concentrations. Although gemfibrozil non-linear
pharmacokinetics have no apparent implications for its
clinical use, CYP2C8 saturation could clinically affect nab-
paclitaxel elimination.
Population pharmacokinetic modeling is a useful tool to
describe and investigate the effect of covariates in drug
variation. A number of population pharmacokinetic models
have described the pharmacokinetics of paclitaxel
monotherapy and have provided important insight into
paclitaxel pharmacokinetics and pharmacodynamics.
Hempel et al. [97] estimated the total paclitaxel plasma CL
to be 6.7 L/h for 13 predominantly male patients treated
with 20–50 mg/m2 as a 1-h infusion. This is in agreement
with the reported values for non-compartmental analyses of
higher doses of paclitaxel. While this study did not report
pharmacokinetic non-linearity, this is likely due to the low
paclitaxel doses that were analyzed. Zuylen et al. [96] were
elegantly able to demonstrate that both non-linear distri-
bution and elimination could be explained by micelle
encapsulation of paclitaxel by Cremophor EL. Hen-
ningsson et al. [98] concluded that the CYP2C8 genotype
did not impact CL of unbound paclitaxel, a finding
disputed by Bergmann et al. [32] who found a small effect
of the CYP2C8*3 variant on paclitaxel CL that may depend
on the ABCB1 genotype [105]. A direct relationship
between liver impairment and paclitaxel elimination was
linked to susceptibility to paclitaxel-induced neutropenia
by Joerger et al. [99]. A model proposed by Li et al. [100]
demonstrated that the similar paclitaxel concentration–time
profiles of nab-paclitaxel and cremophor-diluted paclitaxel
mask discordant paclitaxel tissue concentration profiles.
Based on these findings, the authors conclude that the
paclitaxel plasma profile is a poor marker for clinical
outcome.
Paclitaxel is rarely given as monotherapy, but often
administered in combination with a platinum (cisplatin,
carboplatin) or doxorubicin. There are no reported phar-
macokinetic interactions between paclitaxel and cisplatin
[106–108] or carboplatin [109–111], although the toxicities
of the drugs may be affected by the sequence of their
administration [28]. When doxorubicin and paclitaxel are
administered within a short time interval, the exposure to
doxorubicin is significantly increased [112], which results
in dose-dependent cardiotoxicity [67, 113]. Furthermore, a
number of relevant pharmacokinetic interactions with
paclitaxel have been reported, largely due to inhibition of
the major paclitaxel efflux transporter, P-gp. Recent evi-
dence also indicates that a metabolite of the widely used
anticoagulant drug clopidogrel reduces CYP2C8-mediated
paclitaxel metabolism and can lead to neurotoxicity
[36, 38, 114].
Accumulation of paclitaxel in the peripheral nervous
system has been associated with its toxicity. In mice,
paclitaxel accumulates in the dorsal root ganglia and sciatic
nerve following both single and multiple doses [115].
Paclitaxel was still detectable up to 72 h after a single dose,
which was significantly after the drug could be detected in
the systemic circulation. Following six doses of paclitaxel,
the drug was measurable in these peripheral sites for up to
2 weeks. While such accumulation is not expected to be
reflected in the plasma, these findings in mice are consis-
tent with the observation that cumulative exposure to
paclitaxel is highly correlated with the risk of paclitaxel-
induced sensory neuropathy. Further exploration into the
mechanisms underlying accumulation of paclitaxel in the
peripheral nervous system may lead to better prediction of
an individual patient’s risk for developing sensory
neuropathy.
5 Conclusion
The data presented in this review demonstrates non-lin-
earity in paclitaxel pharmacokinetics when administered as
a short infusion of B6 h. This is largely a result of the
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dilution of paclitaxel in Cremophor EL [24], and possibly
to a lesser extent by saturation of CYP2C8-mediated
metabolism. A strong correlation between paclitaxel Cmax
and CL values and dose is also demonstrated. The limited
data available for paclitaxel T[ 0.05 lmol/L do not allow
for an accurate prediction of its relationship with dose.
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